With legal briefs in, Supreme Court weighs telehealth access for the abortion pill

The U.S. Supreme Court temporarily paused a federal appeals court ruling that would have ended telemedicine access to mifepristone nationwide, allowing prescriptions via telehealth and mail until May 11, 2026. Legal briefs from Louisiana and the Department of Justice (representing the FDA) were filed, with the DOJ notably not defending the FDA’s 2023 telehealth rule, leaving the case’s future uncertain." "article": "A federal appeals court ruling on May 1, 2026, initially blocked telemedicine access to mifepristone nationwide, but the Supreme Court intervened by pausing that decision for one week. As of May 7, telehealth prescriptions for mifepristone remain legal, allowing patients to receive the abortion pill via mail or pharmacy pickup until May 11. The Supreme Court’s next steps depend on Justice Samuel Alito, who could extend the pause or let it expire, potentially ending nationwide telehealth access while legal challenges proceed. Louisiana filed a brief urging the Supreme Court to uphold the appeals court’s ruling, arguing that telemedicine access undermines state abortion bans. The Department of Justice, representing the FDA, did not file a brief defending its 2023 rule allowing telehealth prescriptions, despite the FDA being the defendant in the case. Legal experts noted the DOJ’s inaction as unusual, given the FDA’s authority over prescription drug regulations. The dispute stems from Louisiana’s lawsuit challenging the FDA’s 2023 policy, which expanded telemedicine access for mifepristone during the COVID-19 pandemic. The state, a leader in anti-abortion measures, has previously criminalized out-of-state telemedicine abortions and classified mifepristone as a controlled substance. The Guttmacher Institute estimates telemedicine abortions now account for one-quarter of all U.S. abortions, contributing to a rise in procedures since the *Dobbs* decision overturned *Roe v. Wade*. The FDA’s 2023 rule was critical in maintaining abortion access post-*Dobbs*, as telehealth prescriptions helped offset state-level restrictions. Without the pause, the appeals court’s ruling could reinstate in-person requirements, disrupting access for patients nationwide. The legal saga continues, with the Supreme Court’s decision on the stay—and the broader case—pending further review.